 Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial NTM lung disease that potentially overcomes systemic toxicity and lessens side effects Paper published on clofazimine inhalation suspension demonstrates promising tolerability and toxicokinetics for treating pulmonary NTM infection DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 23, 2023 GLOBE NEWSWIRE ... The post MannKinds Inhaled Clofazimine Will Advance to an Adaptive Phase 2... 